Developer docs
API playgroundTry for free, no card

Search company profiles

Antheia

Full company profile

uuid000052q

Namestring
Antheia
Legal namestring
Antheia, Inc.
Websiteurl
antheia.bio
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Antheia, Inc. is a U.S.-based synthetic biology company founded in 2015 out of the Smolke Lab at Stanford University by Dr. Christina Smolke (CEO) and Dr. Kristy Hawkins (CSO). The company engineers Saccharomyces cerevisiae (baker's yeast) to reconstruct complex plant-derived biosynthetic pathways of 25-30+ heterologous enzymes, enabling fermentation-based production of pharmaceutical Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs) that historically have been sourced through agricultural cultivation or are intractable via chemical synthesis. Antheia operates fermentation at 116,000L commercial scale, has a pipeline of 70+ KSM/API targets across seven therapeutic categories (Neurology, Respiratory, Anti-infective, Oncology, Gastrointestinal, Endocrinology, Hematology), and brought its first commercial product — biosynthetic thebaine, the key ingredient in the opioid overdose reversal drug Narcan — to market in 2024.

Antheia monetizes the platform through direct enterprise B2B sales of KSMs and APIs to global pharmaceutical manufacturers on a quote-based pricing model under Standard Terms and Conditions of Sale, complemented by non-dilutive U.S. government project funding (DPA Title III via BioMaP-Consortium, $21M total as of March 2026) and a strategic manufacturing partnership with TAPI (Teva API) that uses TAPI's 13-site European fermentation footprint to scale production globally. The company maintains a pilot biomanufacturing plant in Menlo Park, California, a new Singapore innovation site, and sells into end-markets framed by the FDA and WHO Essential Medicines Lists, where approximately 78% of API manufacturers sit outside the U.S. and up to 50 new drug shortages per year persist.

The commercial motion is enterprise field sales supported by regulatory and policy engagement (DPA Title III, ASPR), conference participation (SynBioBeta, DCAT, Fierce JPM Week, SK pharmteco symposium), and thought-leadership content. AI/ML and advanced analytics are applied over fermentation datasets and off-gas mass spectrometry across 61 bioreactors to optimize bioprocess performance, but the differentiated output is the physical KSM/API product rather than a stand-alone software offering. Antheia is privately held, has raised more than $175M in cumulative capital over the past year (Series C plus non-dilutive government awards), and is led by founders Christina Smolke (CEO) and Kristy Hawkins (CSO) alongside a recently expanded executive bench (CFO Eric d'Esparbes, COO Zack McGahey, Chief People Officer Heidi Pucel, VP BD Chris Savile, VP Drug Innovation Adam Takos).

Short descriptiontext

Antheia is a synthetic biology company that engineers yeast to produce biosynthetic Key Starting Materials and Active Pharmaceutical Ingredients, serving global pharmaceutical manufacturers and the U.S. government with essential medicines.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMenlo Park, United States
HQ citystring
Menlo Park
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biosynthetic pharmaceutical ingredients, active pharmaceutical ingredients, key starting materials, synthetic biology manufacturing, yeast fermentation platform
Industry3 codes
PRIMARYHLAGAHAD
Controlled Substances / DEA-Scheduled API Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYAFABAEAM
Biological Formulation, Fermentation & Scale-Up Manufacturing
Agriculture & Food Production/Agricultural Inputs & Agrochemicals/Biologicals & Biopesticides (Microbials, Botanicals, Beneficial Insects)
SECONDARYAFAJAJAH
Fermentation Nutrients & Media (Yeast Extracts, Peptones, Nitrogen Sources, Minerals)
Agriculture & Food Production/Food Ingredients & Additives/Cultures & Fermentation Ingredients (Starter Cultures, Probiotics, Yeast)
NAICS code3 codes
  • Medicinal and Botanical Manufacturing325411
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Medicinal Chemicals & Botanical Products2833
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Ingredients (Biosynthetic KSMs and APIs)
Social media profiles1 record
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model4 records
1Sale of biosynthetic pharmaceutical ingredients (KSMs and APIs)
TypeTransaction Fee
Description

B2B sale of pharmaceutical ingredients to drug manufacturers under per-Quotation pricing and Antheia's Standard Terms and Conditions of Sale (quote-based pricing, payment per Quotation, cancellation/reschedule fees tiered by notice window). Primary commercial revenue stream; first commercial delivery of thebaine (Narcan ingredient) executed.

antheia.bio
2U.S. government non-dilutive project funding
TypeManaged Services
Description

Non-dilutive funding from the U.S. Department of Health and Human Services via the BioMaP-Consortium under the Defense Production Act Title III Program to onshore pharmaceutical supply chains ($21M total project investment as of March 2026).

biospace.com
3Strategic CDMO/manufacturing partnerships (capacity-as-a-service)
TypeLicensing Royalties
Description

Partnership with TAPI (Teva API) leverages TAPI's fermentation and API manufacturing footprint in Europe to scale and commercialize biosynthetic APIs/KSMs, effectively monetizing Antheia's platform through partner-operated production at global scale.

prnewswire.com
4Government and foundation grants (historical)
TypeManaged Services
Description

Historically received NSF grants (2016, 2018), NIH grants (2017, 2018), and Phase II SBIR grant (2018), supplementing equity and debt financing during R&D phase.

antheia.bio
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales
Pricing details1 tier
1Quote-based B2B pricing for KSMs and APIs per Quotation; price exclusive of taxes/duties; late payment interest 1.5%/month or max legal rate.
ModelOtherBilling cadenceMulti-year contract
Notes

Price as listed in the Quotation; Seller may revise Purchase Price if Quotation has expired. Cancellation/reschedule fees: 0% if ≥120 days, 25% at 90-119 days, 50% at 60-89 days, 75% at 30-59 days, 100% if <30 days prior to delivery.

antheia.bio
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Antheia manufactures biosynthetic Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs) for essential medicines by engineering Saccharomyces cerevisiae yeast to reconstruct complex plant-derived biosynthetic pathways (25-30 enzymes) and producing them via industrial-scale fermentation at 116,000L. The company's first commercial product is thebaine (the key ingredient used to produce Narcan opioid overdose reversal drug, pain management medications, and alcohol use disorder treatments), with a pipeline of 70+ KSM/API candidates across neurology, respiratory, anti-infective, oncology, gastrointestinal, endocrinology, and hematology.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Reduced production timelines from approximately two years to two weeks for certain biosynthetic compounds.
+4 more records
Product overview1 text field

Antheia offers a platform-plus-modules architecture built around its proprietary Advanced Biosynthesis Platform. The platform is a yeast-based, whole-cell engineering biomanufacturing system organized in four integrated phases (Build, Screen & Develop, Optimize, Scale) that uses reconstructed biosynthetic pathways of 25-30+ enzymes to ferment sugars into complex pharmaceutical ingredients — including Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs) that previously could only be sourced through agricultural cultivation. Built on top of this platform, Antheia's product portfolio centers on commercial and pipeline KSM/API products: Thebaine (commercial stage, used in opioid overdose reversal drug Narcan, pain management, and alcohol use disorder treatments), Oripavine (related opioid KSM/API), Scopolamine (tropane alkaloid), and a deeper pipeline of internally designated products — ANT 104, ANT 105, ANT 106, ANT 108, ANT 206, ANT 302, ANT 401, ANT 402, and ANT 403 — collectively forming a pipeline of 70+ KSMs and APIs spanning Neurology, Respiratory, Anti-infective, Oncology, Gastrointestinal, Endocrinology, and Hematology therapeutic categories on the U.S. FDA Essential Medicines List. Antheia also operates a pilot biomanufacturing facility in Menlo Park, California (at 116,000L scale) and is establishing U.S. manufacturing operations and a Singapore site for drug innovation.

Product and service5 records
1Advanced Biosynthesis Platform
CategoryCore biomanufacturing platform
Description

Antheia's proprietary whole-cell engineering platform that reconstructs complex plant-derived biosynthetic pathways of 25-30+ heterologous enzymes in Saccharomyces cerevisiae yeast, then ferments them into KSMs and APIs at industrial scale (116,000L). Organized in four integrated phases — Build (genomic search and bioinformatics-driven yeast engineering), Screen & Develop (high-throughput strain characterization and downstream process development), Optimize (data-driven analytics, modeling, and AI/ML over fermentation datasets), and Scale (tech transfer to commercial manufacturing including the TAPI CDMO partnership).

2Thebaine
CategoryCommercial biosynthetic KSM/API
Description

Antheia's first commercial biosynthetic product. Thebaine is a benzylisoquinoline alkaloid KSM/API used as the key ingredient for producing Narcan (the opioid overdose reversal drug), pain management medications, and alcohol use disorder treatments. Currently at commercial stage on Antheia's pipeline.

3Oripavine
CategoryPipeline biosynthetic KSM/API
Description

Oripavine is an opiate alkaloid KSM/API produced via Antheia's yeast-based biosynthesis platform and listed in the pipeline alongside Thebaine as a related opioid pharmaceutical ingredient.

4Scopolamine
CategoryPipeline biosynthetic KSM/API
Description

Scopolamine is a tropane alkaloid KSM/API produced via Antheia's yeast-based biosynthesis platform, with therapeutic applications in neurology and gastrointestinal indications. The 2020 Nature publication on biosynthesis of medicinal tropane alkaloids in yeast from the Smolke Lab underpins this product.

5ANT-series pipeline KSM/API products
CategoryPipeline biosynthetic KSM/API
Description

Consolidated pipeline of additional biosynthetic KSM/API candidates designated ANT 104, ANT 105, ANT 106, ANT 108, ANT 206, ANT 302, ANT 401, ANT 402, and ANT 403. Part of Antheia's 70+ KSM/API portfolio spanning Neurology, Respiratory, Anti-infective, Oncology, Gastrointestinal, Endocrinology, and Hematology categories on the U.S. FDA Essential Medicines List.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1U.S. Administration for Strategic Preparedness and Response (ASPR)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-05
Description

ASPR announced March 5, 2026 that it will invest in Antheia for domestic production of thebaine, an active pharmaceutical ingredient used in pain management medications, alcohol use disorder treatments, and opioid overdose reversal drugs. The investment reflects HHS/ASPR efforts to reduce reliance on foreign sources for essential medications and APIs.

aha.org
2BioMaP-Consortium (Biopharmaceutical Manufacturing Preparedness Consortium), funded by U.S. HHS Defense Production Act Title III Program
Strategic tierFlagship / CoreTypeStrategic or Co-development PartnerAnnounced on2026-03-04
Description

Expanded project agreement under which Antheia received an additional $9 million from the U.S. Department of Health and Human Services via BioMaP-Consortium and the DPA Title III Program, bringing total project investment to $21 million. Supports domestic commercial-scale production of two critical pharmaceutical ingredients using Antheia's advanced biosynthesis platform as part of broader onshoring of U.S. pharmaceutical supply chains.

biospace.com
Strategic tierFlagship / CoreTypeStrategic or Co-development PartnerAnnounced on2025-11-20
Description

TAPI and Antheia announced a strategic partnership to scale production of biosynthetic APIs and KSMs using TAPI's fermentation expertise and manufacturing footprint in Europe (13 sites, 4,100 employees, 350+ products, 100+ countries). The collaboration supports Antheia's pipeline of pharmaceutical ingredients including thebaine, expands U.S. production capabilities, and aims to end drug shortages globally. Announced November 2025; ongoing tech transfer and scale-up work led by Antheia's Head of Fermentation Process Development & Scale-Up, Andrew Saarni.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Codexis engineers enzymes and biocatalytic processes for pharmaceutical manufacturing, including APIs and intermediates. It is a direct peer to Antheia given its enzyme-engineering platform for pharmaceutical ingredient production, with comparable B2B pharma ingredient sales motion and overlap in leadership (Chris Savile, Antheia's new VP BD, previously served as Associate Director at Codexis).

TypeDirect peer
Description

Amyris pioneered yeast-based synthetic biology for ingredient production (personal care, flavors, fragrances). It is a direct peer to Antheia given its foundational yeast engineering platform and fermentation-based biomanufacturing model, with notable team overlap (multiple Antheia leaders previously worked at Amyris).

TypeDirect peer
Description

Willow Biosciences develops biosynthetic ingredients for pharmaceutical, consumer, and food applications using engineered yeast. It is a direct peer to Antheia given its biosynthetic API/KSM focus and Chris Savile's previous role as President and CEO of Willow.

TypeDirect peer
Description

Ginkgo Bioworks operates a synthetic biology platform for cell engineering and organism design across multiple industries. It is a direct peer to Antheia given its yeast metabolic engineering capabilities, and Adam Takos (Antheia's new VP of Drug Innovation) previously led a $30M portfolio of drug discovery and yeast engineering programs at Ginkgo.

5Zymergen
TypeDirect peer
Description

Zymergen combined automation, machine learning, and synthetic biology for industrial biomanufacturing before being acquired by Ginkgo Bioworks. It is a comparable peer to Antheia given its fermentation-scale biomanufacturing focus, with notable team overlap (Antheia's COO Zack McGahey and Head of Quality Jesse Ahrendt previously led manufacturing and quality at Zymergen).

6TAPI (Teva API)
TypeBroad incumbent
Description

TAPI is the active pharmaceutical ingredient division of Teva, a global leader in API manufacturing with a large fermentation and small-molecule manufacturing footprint. It is a broad incumbent peer to Antheia given overlapping API manufacturing capabilities and its role as Antheia's strategic partner and global commercialization channel.

TypeDirect peer
Description

LanzaTech operates a synthetic biology platform using engineered microbes to convert waste gases into fuels, materials, and chemicals at commercial scale. It is a direct peer to Antheia given its industrial-scale fermentation-based biomanufacturing model and comparable platform architecture, though focused on different end markets.

TypeEmerging player
Description

Conagen is a synthetic biology company developing fermentation-based ingredients for food, beverage, flavor, and pharmaceutical applications. It is an emerging player peer given its overlapping fermentation platform for high-value ingredients, though it is smaller and less pharma-focused than Antheia.

TypeBroad incumbent
Description

Lonza is a global contract development and manufacturing organization (CDMO) with large-scale fermentation and API manufacturing capabilities serving pharmaceutical customers. It is a broad incumbent peer given its scale, regulatory relationships, and pharma customer base that could compete with or partner around Antheia's biosynthetic platform.

TypeEmerging player
Description

Geltor is a synthetic biology company producing animal-free proteins and ingredients via fermentation. It is an emerging player peer given its fermentation-scale biomanufacturing focus and team overlap (Antheia's Andrew Saarni previously served as Director of Fermentation at Geltor), though Geltor focuses on protein ingredients rather than small-molecule APIs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat7 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles25 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors19 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Antheia

Pharmaceutical Ingredients (Biosynthetic KSMs and APIs)antheia.bio

Antheia is a synthetic biology company that engineers yeast to produce biosynthetic Key Starting Materials and Active Pharmaceutical Ingredients, serving global pharmaceutical manufacturers and the U.S. government with essential medicines.

What Antheia does

Antheia, Inc. is a U.S.-based synthetic biology company founded in 2015 out of the Smolke Lab at Stanford University by Dr. Christina Smolke (CEO) and Dr. Kristy Hawkins (CSO). The company engineers Saccharomyces cerevisiae (baker's yeast) to reconstruct complex plant-derived biosynthetic pathways of 25-30+ heterologous enzymes, enabling fermentation-based production of pharmaceutical Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs) that historically have been sourced through agricultural cultivation or are intractable via chemical synthesis. Antheia operates fermentation at 116,000L commercial scale, has a pipeline of 70+ KSM/API targets across seven therapeutic categories (Neurology, Respiratory, Anti-infective, Oncology, Gastrointestinal, Endocrinology, Hematology), and brought its first commercial product — biosynthetic thebaine, the key ingredient in the opioid overdose reversal drug Narcan — to market in 2024.

Antheia monetizes the platform through direct enterprise B2B sales of KSMs and APIs to global pharmaceutical manufacturers on a quote-based pricing model under Standard Terms and Conditions of Sale, complemented by non-dilutive U.S. government project funding (DPA Title III via BioMaP-Consortium, $21M total as of March 2026) and a strategic manufacturing partnership with TAPI (Teva API) that uses TAPI's 13-site European fermentation footprint to scale production globally. The company maintains a pilot biomanufacturing plant in Menlo Park, California, a new Singapore innovation site, and sells into end-markets framed by the FDA and WHO Essential Medicines Lists, where approximately 78% of API manufacturers sit outside the U.S. and up to 50 new drug shortages per year persist.

The commercial motion is enterprise field sales supported by regulatory and policy engagement (DPA Title III, ASPR), conference participation (SynBioBeta, DCAT, Fierce JPM Week, SK pharmteco symposium), and thought-leadership content. AI/ML and advanced analytics are applied over fermentation datasets and off-gas mass spectrometry across 61 bioreactors to optimize bioprocess performance, but the differentiated output is the physical KSM/API product rather than a stand-alone software offering. Antheia is privately held, has raised more than $175M in cumulative capital over the past year (Series C plus non-dilutive government awards), and is led by founders Christina Smolke (CEO) and Kristy Hawkins (CSO) alongside a recently expanded executive bench (CFO Eric d'Esparbes, COO Zack McGahey, Chief People Officer Heidi Pucel, VP BD Chris Savile, VP Drug Innovation Adam Takos).

Antheia firmographics

Firmographics
Name
Antheia
Legal name
Antheia, Inc.
Website
https://antheia.bio
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Short description
Antheia is a synthetic biology company that engineers yeast to produce biosynthetic Key Starting Materials and Active Pharmaceutical Ingredients, serving global pharmaceutical manufacturers and the U.S. government with essential medicines.
Ownership category
akta.pro rank

Antheia industry classification

Industry
Product category
Pharmaceutical Ingredients (Biosynthetic KSMs and APIs)
NAICS
Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGAHAD
Controlled Substances / DEA-Scheduled API Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYAFABAEAM
Biological Formulation, Fermentation & Scale-Up Manufacturing
Agriculture & Food Production/Agricultural Inputs & Agrochemicals/Biologicals & Biopesticides (Microbials, Botanicals, Beneficial Insects)
SECONDARYAFAJAJAH
Fermentation Nutrients & Media (Yeast Extracts, Peptones, Nitrogen Sources, Minerals)
Agriculture & Food Production/Food Ingredients & Additives/Cultures & Fermentation Ingredients (Starter Cultures, Probiotics, Yeast)

Keywords

  • Biosynthetic pharmaceutical ingredients
  • Active pharmaceutical ingredients
  • Key starting materials
  • Synthetic biology manufacturing
  • Yeast fermentation platform

Where Antheia is headquartered

Location

Headquarters

HQ city
Menlo Park
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Antheia business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. Sale of biosynthetic pharmaceutical ingredients (KSMs and APIs): B2B sale of pharmaceutical ingredients to drug manufacturers under per-Quotation pricing and Antheia's Standard Terms and Conditions of Sale (quote-based pricing, payment per Quotation, cancellation/reschedule fees tiered by notice window). Primary commercial revenue stream; first commercial delivery of thebaine (Narcan ingredient) executed.
  2. U.S. government non-dilutive project funding: Non-dilutive funding from the U.S. Department of Health and Human Services via the BioMaP-Consortium under the Defense Production Act Title III Program to onshore pharmaceutical supply chains ($21M total project investment as of March 2026).
  3. Strategic CDMO/manufacturing partnerships (capacity-as-a-service): Partnership with TAPI (Teva API) leverages TAPI's fermentation and API manufacturing footprint in Europe to scale and commercialize biosynthetic APIs/KSMs, effectively monetizing Antheia's platform through partner-operated production at global scale.
  4. Government and foundation grants (historical): Historically received NSF grants (2016, 2018), NIH grants (2017, 2018), and Phase II SBIR grant (2018), supplementing equity and debt financing during R&D phase.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based B2B pricing for KSMs and APIs per Quotation; price exclusive of taxes/duties; late payment interest 1.5%/month or max legal rate.

Go-to-market motion4 records

Distribution channels3 records

Marketing channels7 records

Antheia product offering

Product offering

Core offering

Antheia manufactures biosynthetic Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs) for essential medicines by engineering Saccharomyces cerevisiae yeast to reconstruct complex plant-derived biosynthetic pathways (25-30 enzymes) and producing them via industrial-scale fermentation at 116,000L. The company's first commercial product is thebaine (the key ingredient used to produce Narcan opioid overdose reversal drug, pain management medications, and alcohol use disorder treatments), with a pipeline of 70+ KSM/API candidates across neurology, respiratory, anti-infective, oncology, gastrointestinal, endocrinology, and hematology.

Product overview

Antheia offers a platform-plus-modules architecture built around its proprietary Advanced Biosynthesis Platform. The platform is a yeast-based, whole-cell engineering biomanufacturing system organized in four integrated phases (Build, Screen & Develop, Optimize, Scale) that uses reconstructed biosynthetic pathways of 25-30+ enzymes to ferment sugars into complex pharmaceutical ingredients — including Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs) that previously could only be sourced through agricultural cultivation. Built on top of this platform, Antheia's product portfolio centers on commercial and pipeline KSM/API products: Thebaine (commercial stage, used in opioid overdose reversal drug Narcan, pain management, and alcohol use disorder treatments), Oripavine (related opioid KSM/API), Scopolamine (tropane alkaloid), and a deeper pipeline of internally designated products — ANT 104, ANT 105, ANT 106, ANT 108, ANT 206, ANT 302, ANT 401, ANT 402, and ANT 403 — collectively forming a pipeline of 70+ KSMs and APIs spanning Neurology, Respiratory, Anti-infective, Oncology, Gastrointestinal, Endocrinology, and Hematology therapeutic categories on the U.S. FDA Essential Medicines List. Antheia also operates a pilot biomanufacturing facility in Menlo Park, California (at 116,000L scale) and is establishing U.S. manufacturing operations and a Singapore site for drug innovation.

Differentiator

Problem solved

Functional benefit

Products and services

  • Advanced Biosynthesis Platform Antheia's proprietary whole-cell engineering platform that reconstructs complex plant-derived biosynthetic pathways of 25-30+ heterologous enzymes in Saccharomyces cerevisiae yeast, then ferments them into KSMs and APIs at industrial scale (116,000L). Organized in four integrated phases — Build (genomic search and bioinformatics-driven yeast engineering), Screen & Develop (high-throughput strain characterization and downstream process development), Optimize (data-driven analytics, modeling, and AI/ML over fermentation datasets), and Scale (tech transfer to commercial manufacturing including the TAPI CDMO partnership).
  • Thebaine Antheia's first commercial biosynthetic product. Thebaine is a benzylisoquinoline alkaloid KSM/API used as the key ingredient for producing Narcan (the opioid overdose reversal drug), pain management medications, and alcohol use disorder treatments. Currently at commercial stage on Antheia's pipeline.
  • Oripavine Oripavine is an opiate alkaloid KSM/API produced via Antheia's yeast-based biosynthesis platform and listed in the pipeline alongside Thebaine as a related opioid pharmaceutical ingredient.
  • Scopolamine Scopolamine is a tropane alkaloid KSM/API produced via Antheia's yeast-based biosynthesis platform, with therapeutic applications in neurology and gastrointestinal indications. The 2020 Nature publication on biosynthesis of medicinal tropane alkaloids in yeast from the Smolke Lab underpins this product.
  • ANT-series pipeline KSM/API products Consolidated pipeline of additional biosynthetic KSM/API candidates designated ANT 104, ANT 105, ANT 106, ANT 108, ANT 206, ANT 302, ANT 401, ANT 402, and ANT 403. Part of Antheia's 70+ KSM/API portfolio spanning Neurology, Respiratory, Anti-infective, Oncology, Gastrointestinal, Endocrinology, and Hematology categories on the U.S. FDA Essential Medicines List.

Quantifiable outcome

  • Reduced production timelines from approximately two years to two weeks for certain biosynthetic compounds.
  • +4 more outcomes

Companies that use Antheia

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Antheia technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Antheia partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and flagship / core.

  • U.S. Administration for Strategic Preparedness and Response (ASPR)coreStrategic or Co-development Partner · 5 March 2026ASPR announced March 5, 2026 that it will invest in Antheia for domestic production of thebaine, an active pharmaceutical ingredient used in pain management medications, alcohol use disorder treatments, and opioid overdose reversal drugs. The investment reflects HHS/ASPR efforts to reduce reliance on foreign sources for essential medications and APIs.
  • BioMaP-Consortium (Biopharmaceutical Manufacturing Preparedness Consortium), funded by U.S. HHS Defense Production Act Title III Programflagship / coreStrategic or Co-development Partner · 4 March 2026Expanded project agreement under which Antheia received an additional $9 million from the U.S. Department of Health and Human Services via BioMaP-Consortium and the DPA Title III Program, bringing total project investment to $21 million. Supports domestic commercial-scale production of two critical pharmaceutical ingredients using Antheia's advanced biosynthesis platform as part of broader onshoring of U.S. pharmaceutical supply chains.
  • TAPI (Technology and API Services, a Teva API business)flagship / coreStrategic or Co-development Partner · 20 November 2025TAPI and Antheia announced a strategic partnership to scale production of biosynthetic APIs and KSMs using TAPI's fermentation expertise and manufacturing footprint in Europe (13 sites, 4,100 employees, 350+ products, 100+ countries). The collaboration supports Antheia's pipeline of pharmaceutical ingredients including thebaine, expands U.S. production capabilities, and aims to end drug shortages globally. Announced November 2025; ongoing tech transfer and scale-up work led by Antheia's Head of Fermentation Process Development & Scale-Up, Andrew Saarni.

Scale indicators12 records

Recent moves9 records

Expansion highlights6 records

Antheia competitors and assessment

Company assessment

Direct peers

  • Codexis: Codexis engineers enzymes and biocatalytic processes for pharmaceutical manufacturing, including APIs and intermediates. It is a direct peer to Antheia given its enzyme-engineering platform for pharmaceutical ingredient production, with comparable B2B pharma ingredient sales motion and overlap in leadership (Chris Savile, Antheia's new VP BD, previously served as Associate Director at Codexis).
  • Amyris: Amyris pioneered yeast-based synthetic biology for ingredient production (personal care, flavors, fragrances). It is a direct peer to Antheia given its foundational yeast engineering platform and fermentation-based biomanufacturing model, with notable team overlap (multiple Antheia leaders previously worked at Amyris).
  • Willow Biosciences: Willow Biosciences develops biosynthetic ingredients for pharmaceutical, consumer, and food applications using engineered yeast. It is a direct peer to Antheia given its biosynthetic API/KSM focus and Chris Savile's previous role as President and CEO of Willow.
  • Ginkgo Bioworks: Ginkgo Bioworks operates a synthetic biology platform for cell engineering and organism design across multiple industries. It is a direct peer to Antheia given its yeast metabolic engineering capabilities, and Adam Takos (Antheia's new VP of Drug Innovation) previously led a $30M portfolio of drug discovery and yeast engineering programs at Ginkgo.
  • Zymergen: Zymergen combined automation, machine learning, and synthetic biology for industrial biomanufacturing before being acquired by Ginkgo Bioworks. It is a comparable peer to Antheia given its fermentation-scale biomanufacturing focus, with notable team overlap (Antheia's COO Zack McGahey and Head of Quality Jesse Ahrendt previously led manufacturing and quality at Zymergen).
  • LanzaTech: LanzaTech operates a synthetic biology platform using engineered microbes to convert waste gases into fuels, materials, and chemicals at commercial scale. It is a direct peer to Antheia given its industrial-scale fermentation-based biomanufacturing model and comparable platform architecture, though focused on different end markets.

Broad incumbents

  • TAPI (Teva API): TAPI is the active pharmaceutical ingredient division of Teva, a global leader in API manufacturing with a large fermentation and small-molecule manufacturing footprint. It is a broad incumbent peer to Antheia given overlapping API manufacturing capabilities and its role as Antheia's strategic partner and global commercialization channel.
  • Lonza: Lonza is a global contract development and manufacturing organization (CDMO) with large-scale fermentation and API manufacturing capabilities serving pharmaceutical customers. It is a broad incumbent peer given its scale, regulatory relationships, and pharma customer base that could compete with or partner around Antheia's biosynthetic platform.

Emerging players

  • Conagen: Conagen is a synthetic biology company developing fermentation-based ingredients for food, beverage, flavor, and pharmaceutical applications. It is an emerging player peer given its overlapping fermentation platform for high-value ingredients, though it is smaller and less pharma-focused than Antheia.
  • Geltor: Geltor is a synthetic biology company producing animal-free proteins and ingredients via fermentation. It is an emerging player peer given its fermentation-scale biomanufacturing focus and team overlap (Antheia's Andrew Saarni previously served as Director of Fermentation at Geltor), though Geltor focuses on protein ingredients rather than small-molecule APIs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks7 records

Key highlights7 records

Customer concentration

Antheia social profiles

Digital presence

Antheia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Antheia leadership team

Management profile

Number of profiles

Profiles25 records

Antheia subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Antheia funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Antheia M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Antheia

What does Antheia do?

Antheia manufactures biosynthetic Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs) for essential medicines by engineering Saccharomyces cerevisiae yeast to reconstruct complex plant-derived biosynthetic pathways (25-30 enzymes) and producing them via industrial-scale fermentation at 116,000L. The company's first commercial product is thebaine (the key ingredient used to produce Narcan opioid overdose reversal drug, pain management medications, and alcohol use disorder treatments), with a pipeline of 70+ KSM/API candidates across neurology, respiratory, anti-infective, oncology, gastrointestinal, endocrinology, and hematology.

Is Antheia a public or private company?

Antheia is a private company. It is classified as venture growth investor backed and is currently operating.

When was Antheia founded?

Antheia was founded in 2015. It employs 51 to 100 people.

Where is Antheia based?

Antheia is headquartered in Menlo Park, United States, in the North America region.

How does Antheia make money?

Four revenue lines are on record. Sale of biosynthetic pharmaceutical ingredients (KSMs and APIs) is the primary driver. The others are U.S. government non-dilutive project funding, strategic CDMO/manufacturing partnerships (capacity-as-a-service) and government and foundation grants (historical).

Who are Antheia's main competitors?

Direct peers on record are Codexis, Amyris, Willow Biosciences, Ginkgo Bioworks, Zymergen and LanzaTech. Broad incumbents are TAPI (Teva API) and Lonza. Emerging players are Conagen and Geltor.

Does Antheia have an API?

No public API is recorded for Antheia.

What industry is Antheia in?

Antheia's product category is Pharmaceutical Ingredients (Biosynthetic KSMs and APIs). Its primary akta.pro industry code is HLAGAHAD, Controlled Substances / DEA-Scheduled API Manufacturing, with a secondary code of AFABAEAM, Biological Formulation, Fermentation & Scale-Up Manufacturing. Its NAICS code is 325411 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
In VivoThe War Of Medicines: US Government To Loan $80m For Domestic Generics ManufacturingThe US Department of War's Office of Strategic Capital agreed to an $80m conditional loan to Antheia to scale domestic production of generic KSMs and APIs. The loan is subject to the company satisfying financial, legal, technical, investment, and due diligence requirements.FiercePharmaAntheia lands $80M conditional loan from Trump administration to onshore drug manufacturingAntheia received a conditional $80 million loan from the Trump administration's Office of Strategic Capital to onshore U.S. drug manufacturing. The company estimates the U.S. relies on foreign countries for roughly 90% of its key starting materials and active pharmaceutical ingredients, with China responsible for 41%. The loan is contingent on meeting financial, legal, and technical requirements.Endpoints NewsAntheia gets $80M conditional DOD loan to onshore to the USAntheia, a biosynthesis manufacturer, won a conditional $80 million loan from the US Department of Defense. The loan is intended to boost domestic production of generic biosynthesis products.citybizAntheia Secures Conditional $80 Million Federal Loan Commitment for U.S. Pharmaceutical ManufacturingAntheia secured a conditional $80 million loan commitment from the U.S. Department of War's Office of Strategic Capital to expand domestic pharmaceutical ingredient manufacturing. The company cites a 90% U.S. dependence on foreign suppliers for key ingredients, and the financing is subject to due diligence before closing.PR NewswireAntheia Secures $80 Million Conditional Funding Commitment from Department of War's Office of Strategic CapitalAntheia announced a conditional commitment from the U.S. Department of War's Office of Strategic Capital for a direct loan of up to $80 million. The financing supports its U.S. manufacturing strategy to onshore critical pharmaceutical ingredients, addressing the U.S.'s 90% foreign dependence on key starting materials and active pharmaceutical ingredients.HindustantimesDonald Trump links a $100 million Kentucky drug plant investment to Republican victory in the 2026 midterm electionsTrump announced a $100 million investment in Antheia's drug manufacturing facility in Winchester, Kentucky, contingent on Republicans winning the November 3 midterms. He said Democrats would not be able to carry out the project. The announcement was made at a rally in Highland Heights, Kentucky.EIN PresswireDonald Trump Makes a $100M Promise to Kentucky 'If the Republicans Win' Midterm ElectionsTrump promised a $100 million pharmaceutical investment in Winchester, Kentucky, for Antheia if Republicans win the November midterms. The funding details, timing, and facility operations remain unclear, and the project has not been approved. Antheia has previously received $9 million and $12 million in federal support.Mirage NewsWar Department Commits $80 Million Loan to AntheiaThe U.S. Department of Defense's Office of Strategic Capital announced an $80 million conditional loan to Antheia, Inc. to scale domestic production of key starting materials and active pharmaceutical ingredients. The investment aims to reduce reliance on foreign manufacturing and support President Trump's Executive Order 13944. Antheia will use bioengineered yeast to produce these materials in a one-step fermentation process.YahooTrump makes $100 million promise to Kentucky if GOP wins midtermsTrump promised $100 million to pharmaceutical company Antheia for a Kentucky drug manufacturing facility, conditional on Republicans winning the midterms. The investment would exceed prior federal awards to Antheia, but details on the project were not disclosed.YahooTrump stumps for GOP candidates, calls out Charles Booker and other Dems at KY rallyAt a Northern Kentucky rally, President Trump warned Democrats of midterms and promised $100 million to Antheia for a drug facility if Republicans win. He attacked Charles Booker, calling him a radical, and urged support for Ed Gallrein and Ralph Alvarado. Democrats responded with criticism of his promises and approval drop.